Saturday, March 2, 2024



A Breakthrough Biosimilar as Disease-Modifying Therapy for Multiple Sclerosis Treatment

Tyruko has been indicated as a single disease-modifying therapy (DMT) for adults diagnosed with highly active Relapsing-Remitting Multiple Sclerosis (RRMS), a designation also approved...

Novartis Has Completed The Spin-Off of Sandoz, Its Generics and Biosimilars Division

Novartis successfully carried out the Sandoz Spin-off, marking the conclusion of its strategic transformation into prominent pharmaceuticals. This separation was executed through a dividend-in-kind...

Latest news

Sticky Image